Does exercise training prescription based on estimated heart rate training zones exceed the ventilatory anaerobic threshold in patients with coronary heart disease undergoing usual-care cardiovascular rehabilitation?: A United Kingdom perspective

Pymer, Sean, Nichols, Simon, Prosser, Jon, Birkett, Stefan, Carroll, Sean and Ingle, Lee

Available at http://clok.uclan.ac.uk/28581/


It is advisable to refer to the publisher’s version if you intend to cite from the work. http://dx.doi.org/10.1177/2047487319852711

For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.

For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the http://clok.uclan.ac.uk/policies/
Does exercise training prescription based on estimated heart rate training zones exceed the ventilatory anaerobic threshold in patients with coronary heart disease undergoing usual-care cardiovascular rehabilitation?: A United Kingdom perspective.

Sean Pymer¹
Simon Nichols²*
Jonathon Prosser³
Stefan Birkett⁴
Sean Carroll⁵
Lee Ingle⁵

Corresponding Author: *Dr Simon Nichols, Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, UK (S.J.Nichols@shu.ac.uk)

Institutions:
¹Academic Vascular Surgical Unit Hull York Medical School, Hull, UK.
²Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, UK
³Atrium Health, Centre for Exercise and Health, Coventry, UK
⁴School of Sport & Wellbeing, University of Central Lancashire, Preston, UK
⁵Department of Sport, Health & Exercise Science, University of Hull, Hull, UK.

Funding – Sean Pymer is funded by a University of Hull PhD scholarship.

Word Count 3,128 (excluding abstract, tables, figures, references).
Abstract

**Background:** In the United Kingdom (UK), exercise intensity is prescribed from a fixed percentage range (% heart rate reserve; %HRR) in cardiac rehabilitation (CR) programmes. We aimed to determine the accuracy of this approach by comparing it with an objective, threshold-based approach incorporating the accurate determination of ventilatory anaerobic threshold (VAT). We also aimed to investigate the role of baseline cardiorespiratory fitness status, and exercise testing mode dependency (cycle v treadmill ergometer) on these relationships.

**Design/Methods:** A maximal cardiopulmonary exercise test was conducted on a cycle ergometer or a treadmill before and following usual-care circuit training from two separate CR programmes from a single region in the UK. The heart rate corresponding to VAT was compared to current heart rate-based exercise prescription guidelines.

**Results:** We included 112 referred patients (61 years [59-63]; body mass index 29 kg·m⁻² [29-30]; 88% male). There was a significant but relatively weak correlation \((r=0.32; \ P=0.001)\) between measured and predicted %HRR, and values were significantly different from each other \((P=0.005)\). Within this cohort, we found that 55% of patients had their VAT identified outside of the 40-70% predicted HRR exercise training zone. In the majority of participants (45%), the VAT occurred at an exercise intensity <40% HRR). Moreover, 57% of patients with low levels of cardiorespiratory achieved VAT at <40% HRR. Whereas, 30% of patients with higher fitness achieved their VAT at >70% HRR. VAT was significantly higher on the treadmill than the cycle ergometer \((P<0.001)\).

**Conclusion:** In the UK, current guidelines for prescribing exercise intensity are based on a fixed percentage range. Our findings indicate that this approach may be inaccurate in a large proportion of patients undertaking CR.

**Word Count:** 274 words

**Key words:** cardiac rehabilitation, exercise prescription, cardiorespiratory fitness, ventilatory anaerobic threshold.
Introduction

Cardiovascular rehabilitation (CR) is a multi-disciplinary secondary prevention programme that has been shown to contribute to reduced hospital admissions, and improvements in patient quality of life, following a cardiac event. Historically, a 1% improvement in peak oxygen uptake (VO$_{2\text{peak}}$) resulting from exercise-based CR, was thought to confer a 2% reduction in premature mortality. Similarly, every 3.5 ml·kg$^{-1}$·min$^{-1}$ increment in VO$_{2\text{peak}}$ has been associated with a 12-13% survival benefit in men referred for exercise testing. Therefore, it is essential that the prescribed dose of exercise is sufficient to stimulate improvements in VO$_{2\text{peak}}$ following CR. Recent systematic reviews and meta-analyses have shown that increased exercise intensity is an important factor in achieving superior outcomes in patients with cardiovascular disease.

The prescribed dose of exercise can be influenced by manipulating exercise frequency, duration, type/mode, and/or intensity [exercise dose]. In the United Kingdom (UK), current long-term exercise training guidelines for patients undertaking CR, recommend exercise training intensities between 40-70% heart rate reserve (HRR), oxygen uptake reserve (VO$_2$R), or a Borg rating of perceived exertion (RPE) between 11-14. Both continuous and interval training at an objective physiological threshold has been shown to have a beneficial impact by improving VO$_{2\text{peak}}$. Training at or above the ventilatory anaerobic threshold (VAT), often referred to as the first ventilatory threshold (VT1), indicates the point above which, further increments in work rate are increasingly supplemented through anaerobic metabolism. Despite being associated with mild metabolic perturbations, regular exercise bouts conducted at work rates equivalent to VAT are well tolerated, and induce physiological adaptation leading to improved cardiorespiratory fitness (CRF) and other cardiovascular risk factors. However, whilst...
work rates corresponding to VAT may represent a minimum intensity needed to improve CRF, metabolic gas equipment and calibrated ergometers are often not available in a CR setting in the UK. Prescribing exercise as a percentage of measured HRR, or most typically estimated HRR, is often a more practical and realistic alternative in UK cardiac rehabilitation settings.\textsuperscript{(10)}

The 40\% HRR threshold is cited as the lowest effective exercise intensity for improving CRF in patients undertaking CR.\textsuperscript{(10, 12)} The individual VAT is widely accepted to occur between 45-65\% HRR in healthy and cardiac patients,\textsuperscript{(8)} with lower values reported in patients with a chronic cardiovascular disease.\textsuperscript{(10)} However, the distribution of VAT values, and its relation to exercise capacity, is unclear in patients undertaking CR. How commonly VAT occurs within discrete exercise intensity ranges is also under-reported in patients with coronary artery disease. Tan et al\textsuperscript{(21)} showed that the mean VAT was equal to 82\% of maximal heart rate (HR), in 19 cardiac patients referred for a cardiopulmonary exercise test (CPET) prior to CR,\textsuperscript{(21)} However, the mode of exercise testing may also influence when an individual’s VAT occurs.

In the UK, the mode of exercise testing varies between CR programmes. This means that a patient’s exercise prescription could be based on a number of different submaximal exercise tests, including the 6-min walk test, incremental shuttle walk test, step test, or cycle ergometry. The differing metabolic responses to cycling compared with walking may affect a patient’s peak oxygen uptake ($V\text{O}_2\text{peak}$), and the occurrence of VAT. This, in turn, may significantly affect the accuracy of exercise intensity prescription. These issues have not been addressed sufficiently within UK guidelines for exercise prescription in CR programmes. This information may help practitioners to optimise a patient’s initial exercise
prescription and maximise the improvements associated with exercise training programmes. This is especially important when the frequency and duration of CR sessions are finite. We aimed to determine the accuracy of the standard UK approach for prescribing exercise in patients undertaking CR by comparing it with objective measures of exercise prescription, namely $V\dot{O}_{2\text{peak}}$ and VAT. Secondary aims were to determine how exercise modality (exercise testing with cycle versus treadmill ergometer), and baseline levels of CRF affected the concordance of VAT and HRR measures.

Methods

Data was collated from the baseline assessment of two separate cohorts who undertook a maximal effort CPET to volitional exhaustion prior to commencing a CR programme. The methods for these studies have previously been reported. Ethical approval was provided by the Yorkshire and Humber – Sheffield National (12/YH/0072) and Humber Bridge NHS (12/YH/0278) Research Ethics Committees. Briefly, patients were recruited following a referral to CR for angina, myocardial infarction (MI), coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI). Patients attended a baseline study assessment, where written informed consent was obtained. CPET was conducted on a cycle ergometer following a 25W incremental protocol, or on a treadmill following the modified Bruce protocol, adopting previously outlined test termination and maximal effort criteria. Breath-by-breath metabolic gas exchange data were collected using an Innocor (Innovision, Glamsbjerg, Denmark) or Oxycon-Pro metabolic cart (Jaeger, Hoechburg, Germany), respectively, which were calibrated according to manufacturers’ instructions and current recommendations. Peak values were averaged over the final 30
seconds of the CPET. VO$_{peak}$ was reported in absolute values (L·min$^{-1}$) and standardised to each patient's body mass (ml·kg$^{-1}$·min$^{-1}$). Individualised VAT was independently determined by two investigators (using the average of the middle five of every seven breaths plotted in the V-slope method, and verified using the ventilatory equivalents.(14, 27) Where investigators reported different VAT values, a third reviewer was consulted and the threshold value agreed by consensus. The VAT was reported in L·min$^{-1}$ and ml·kg$^{-1}$·min$^{-1}$ and expressed as a percentage of directly-determined and predicted VO$_{peak}$.(28) The HR at VAT was then established and reported as a ratio of HRmax and HRR determined from CPET, and as a ratio of predicted HRmax and HRR with relevant adjustment for the effects of beta-blockade on maximal heart rates as follows [10]):

\[
(205.8 - (0.685 \times \text{age})) - \text{resting heart rate (}-30 \text{ beats per min if taking beta-blockers})
\]

To characterise where a patient's VAT occurred in relation to established training zones, the VAT values were categorically assigned to exercise intensity groups of <40%, 40-49%, 50-59%, 60-69%, 70%, and >70% of measured, and predicted HRR. Adjustment for β-blockades were made where appropriate,(12). We assessed how many patients had a VAT that occurred within the exercise training intensity ranges recommended by UK CR guidelines, namely 40-70% HRR, or an RPE between 11-14.(11, 12) Patients were sub-categorised according to individual CRF levels as low (<5 METs for women, <6 METs for men), moderate (5<7 METs for women, 6<8 METs for men), and high CRF (≥7 METs for women, ≥ 8 METs for men), based on exercise capacity (MET) thresholds derived from the international literature and previously applied to cardiac patients in the UK.(29) These sub-groups were then
categorised based on the HRR zone that the individualised VAT occurred within. We also conducted sub-analyses on patients who undertook their CPET either on a treadmill or cycle ergometer.

Data analysis

Statistical analysis was conducted using SPSS version 24 (IBM, NY, USA). When data was not normally distributed, normalisation of the distribution was attempted using log_{10} transformation. Logarithmically transformed data was analysed in its transformed state and reported as an arithmetic mean to allow for meaningful interpretation. Normally distributed and transformed data were analysed using a univariate general linear model with significance set at arbitrary level (P<0.05), and is presented as mean (95% confidence intervals), and partial-eta squared (η^2_p) effect sizes, with 0.01, 0.06, and 0.14 denoting small, moderate, and large effects, respectively (30). For non-normally distributed data, a Mann-Whitney U test was conducted with median and range reported. Categorical data was analysed using a Chi-squared test of independence and reported as percentage and frequency. When ≥1 cell had an expected value <5, the Fisher’s exact test was used.

Results

Patient Characteristics

One-hundred and twelve (n=112) cardiac patients were included for analysis (61.3 years [59.4-63.1]; 29.3 kg·m^{-2} [28.5-30.1]; 88% male). Forty-two patients (n=42; 37.5%) undertook their CPET on a cycle ergometer. Patients on a cycle ergometer achieved 79.1% of their predicted HRmax [74.6-83.6%], an RPE of 18 [17-18], and a peak respiratory exchange ratio
(RER) of 1.02 [1.00-1.05]. Seventy (n=70) patients undertook CPET on a treadmill. Patients conducting CPET on a treadmill achieved 82.3% [79.7-84.9%] of predicted HRmax, an RPE of 17.8 [17.3-18.3], and a peak RER of 1.09 [1.06-1.11]). 77% and 86% of the patients undergoing cycle and treadmill testing, respectively, were prescribed beta-blockers. The majority of patients had a diagnosis of myocardial infarction (MI) with primary (32.5%) or elective (28.9%) PCI. There was a greater prevalence of active smokers (P=0.017) in those that conducted a CPET on a cycle ergometer. There were significant between-group differences for age (P=0.012; η²p =0.054), and resting HR (mean difference 5.8bpm (95% CI 1.0-10.5bpm) P=0.032; Table 1) between the test modality groups. 42 out of 112 patients, were classified within the lower cardiorespiratory fitness group, 50 in the moderate-fit group, and 20 in the high-fit group (Table 2).

VAT, HRR zones, and CRF categories

Measured HRR (72 ± 15 bpm) derived from maximal CPET demonstrated only a modest correlation with predicted HRR (77.99 ± 20.42bpm) (using current UK CR guidelines (r=0.32; P=0.001). However, the directly determined and predicted HRR/peak HR variables were significantly different from each other (mean difference = 6.74bpm (95% CI 2.99-10.49bpm) P=0.001). The VAT occurred within 40-70% of directly determined HRR range in 61.6% of patients. In the remaining 38.4% of patients, 33.9% achieved their VAT at <40% HRR, and in 4.5% of patients, their VAT did not occur until >70% HRR. For predicted HRR, VAT occurred within 40-70% HRR in 44.6% of patients. Of the remaining 55.4% of patients, 45.4% achieved VAT at <40% HRR, and 9.8% at >70% HRR (Table 2).
The VAT occurred between 40-70% of predicted HRR in 21.4% of patients undertaking cycling exercise. The majority (76.2%) of patients exceeded the VAT at <40% HRR. For patients undertaking CPET on a treadmill, 58.5% of patients had a VAT that occurred between 40-70% of predicted HRR, and 27.1% had a VAT that occurred at <40% HRR. Interestingly, the VAT occurred between 40-70% of predicted HRR in 35.8% of patients that were categorised as having a low CRF. 57.1% of patients exceeded their VAT at <40% of their HRR. For higher-fit patients, VAT occurred between 40-70% of predicted HRR in 50% of patients, at <40% HRR in 20%, and >70% HRR for the remaining 30% of patients (Table 2).

Figure 1 shows the inter-quartile range for VAT as a percentage of predicted HRR, based on CRF category, and exercise testing modality. The VAT occurred at a higher percentage of VO$_{2peak}$ in patients with a higher CRF. This observation was also evident when CPET was conducted on a treadmill for all CRF categories, but most apparently in the moderate and high-fit groups.

Directly measured compared with predicted cardiorespiratory fitness variables

Mean VO$_{2peak}$ was not significantly different between exercise modality groups in absolute units ($P=0.644; \eta_p^2=0.002$), or relative to body mass ($P=0.359; \eta_p^2=0.008$) (Table 3). However, absolute ($P=0.027$) and relative ($P=0.001$) VAT was significantly different across the different CRF groups. VAT occurred at a higher percentage of predicted ($P=0.003; \eta_p^2=0.08$) and measured VO$_{2peak}$ ($P<0.001; \eta_p^2=0.151$), and HRR ($P<0.001; \eta_p^2=0.132$) in patients exercising on the treadmill. Measured HRR ($P=0.012; \eta_p^2=0.056$), and HR at VAT ($P=0.016; \eta_p^2=0.052$) were significantly higher in the treadmill group. There was a significant
between-group difference for predicted HRmax adjusted for β-blockade ($P=0.003; \text{Table } 4$).

However, there was no difference in predicted HRR ($P=0.863\quad \eta^2_p \leq 0.001$) or VO$_{2\text{peak}}$ between groups ($P=0.815, \quad \eta^2_p < 0.001$). Figures 2a and 2b highlight individual case studies which demonstrate how the predicted HRR method can either over- or under- estimate individualised exercise prescription versus directly determined HRR and VAT.

Discussion

This study aimed to determine the accuracy of the standard UK approach for prescribing exercise in patients undertaking CR. This method of determining target heart rates for exercise training in cardiac patients relies largely on predictive methods for determining maximal HR (including patients taking beta-blockade). We sought to compare it with a more objective measure of exercise prescription, namely the VAT derived from respiratory gas exchange during a maximal CPET. Our findings indicate that current UK CR exercise prescription guidelines appear susceptible to substantial inaccuracy with more than half of our cohort achieving a VAT outside the recommended target range of 40-70% HRR. We found that 45% of patients had VAT identified at <40% HRR, and in 9% of patients, VAT was identified at >70% HRR, suggesting that the required exercise intensity spectrum is wider than the recommended 40-70 HRR%.

When considering baseline cardiorespiratory fitness, the proportion of patients whose VAT occurred outside the guidelines increased. 57% of low-fit patients achieving VAT at <40% HRR, and 30% of high-fit patients achieving VAT at >70% HRR, confirming that VAT occurs later with increasing CRF in cardiac patients.(31) For those who achieved VAT at <40% HRR,
their exercise prescription may overly exceed VAT and prove too challenging, whilst for
those that achieve VAT >70%HRR, their prescription is unlikely to induce a training stimulus
and prove too easy. We speculate that this may contribute to the 23% attrition rate recently
reported in UK CR,(32) as some patients overly exceed their training stimulus (i.e. low fit
patients), which may be uncomfortable, whilst some do not reach it, thus providing minimal
benefit (i.e. high fit patients), both of which may cause patients to discontinue CR.

Therefore, a one size fits all approach, relying on predictive methods for maximal HR and
estimated HRR to prescribe exercise appears ineffective. Exercise prescription within cardiac
rehabilitation settings needs to be more accurate, patient specific and fine-tuned, ideally
based on ventilatory markers, actual HRR and baseline fitness category determined via
CPET.(33) One option could be to shift from ‘range-based’ to ‘threshold-based’ CR exercise
prescription, with moderate-high intensity exercise, corresponding to work rates between
VAT and critical power, being recommended.(17) Based on the current data, CPET would aid
prescription to ensure that all patients achieved VAT during CR, whilst also ensuring it is not
overly exceeded. This is important given that certain cardiac patients, namely those who
may be more deconditioned, often perform activities of daily living at levels of VO\textsubscript{2} that
exceed VAT.(34) Therefore, exercising in steady-state conditions above VAT is vital for these
patients, but may not be possible if it is exceeded. In the late 1970s, limitations in the
relative percent method (i.e %HRR) for prescribing exercise intensity were identified, with a
study by Katch et al showing this method failed to consider individual metabolic
differences,(35) yet it is still a recommended approach today.(8,10) More recent
investigations have proposed a more individualised exercise prescription based on
ventilatory thresholds to personalise individualised training load based on metabolic
responses.(36, 37) Recently, Weatherwax et al reported that in sedentary adults, 12 weeks
of aerobic exercise training based on an individualised exercise prescription using VAT had a
greater effect on the incidence of training response compared to a standardised approach
using HRR. While the exact mechanisms are still not entirely understood, it is believed that
exercise intensity prescribed with the use of ventilatory thresholds takes into consideration
individual metabolic characteristics which are overlooked when using relative percent
methods.\(^{(38)}\)

The current data also indicate that VAT is mode-dependant for the overall cohort and across
all three CRF categories. Similar to previous suggestions,\(^{(17)}\) VAT occurred at around 50%
HRR on the treadmill but is 12-15% lower on the cycle. A similar relation has also been
observed in patients with chronic heart failure.\(^{(39)}\) This mode dependency is also evident in
terms of predicted HRR zones, which are adopted in most UK CR centres, with >75% of
patients on a cycle ergometer achieving VAT at <40% HRR, compared with just 27% of
patients exercising on a treadmill. Previous research has identified a VAT mode dependency
in cardiac patients based on VO\(_2\).\(^{(40)}\) The current results differ somewhat as they show a
mode dependency for patients who are yet to begin as opposed to those who have finished
CR. Furthermore, in the current study this mode dependency is expressed using HRR, which
is adopted in most CR centres, rather than VO\(_2\).

UK CR is provided by the state-funded National Health Service, unlike CR operating in other
international and EU countries,\(^{(15)}\) the integration of CPET equipment is not currently
incorporated into most UK centres and may prove to be prohibitive.\(^{(41)}\) Another possible
solution could be to increase the upper intensity limit of exercise prescription in line with
international guidelines at 80% HRR, especially for patients in a higher fit category.\(^{(10, 42)}\)
Of the 10 patients whose VAT occurred at >70% HRR, 6 achieved VAT at <80% HRR. This suggests that increasing the upper range of exercise prescription guidelines could be helpful to a small cohort of patients, and provide greater scope for training progression in those that could tolerate it; aligning UK guidelines closer to those seen internationally. (43) This does not however, address the issue for those who achieved VAT at <40%. A further alternative to personalise exercise prescription across the whole spectrum would be to identify the HR range corresponding to an RPE of 11-13, given that VAT has been shown to occur around this point (44, 45). Submaximal testing is routinely performed in UK CR and identification and utilisation of the HR between these points during testing could ensure more patients are exercising at or around the VAT. One caveat to such an option is that RPE is a subjective tool, meaning that appropriate anchoring of key values would be required for each patient, and this would need to be applied consistently within and between each CR centre in the UK.

To be able to confidently prescribe an individualised exercise programme in a safe and effective manner can be challenging in a cardiac population. The healthcare professional must be able to account for medication usage, presence of non-CV co-morbidities, and for example, adverse events during exercise testing. Hansen and colleagues [46] showed significant inter-clinician variance in prescribing exercise for patients with different CVDs, highlighting the challenges posed. Further training and education is key, however, digital resources are available to assist practitioner decision-making processes. For example, the European Association of Preventive Cardiology recently developed the Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool. [47] The EXPERT tool is an interactive, digital training and decision support system that assists healthcare professionals in prescribing clinically effective and medically safe exercise training programmes for CVD.
patients. The adoption of tools such as EXPERT should be more widely encouraged and facilitated to support decision making processes around exercise prescription in cardiac populations. The impact of their utility within clinical practice could then be audited to determine changes in efficacy.

Limitations

The key limitation is that the two groups are made up of separate patients who varied on some baseline characteristics. Ideally, all patients would have completed a CPET using both modalities to reduce any individual effect.

Conclusion

To our knowledge, this is the first study of its kind to explore VAT in terms of prescribed HRR zones for cardiac patients to identify the accuracy of current UK CR exercise prescription guidelines. For a large proportion of patients, the guidelines are inaccurate with many patients achieving VAT at <40% HRR, meaning their exercise prescription may be overly challenging. Conversely, 30% of high-fit patients achieved VAT at >70% HRR, meaning their prescription may be too conservative to provide a stimulus. This under/over-prescription may lead patients to unnecessarily discontinue their CR (see Figures 2a and 2b). Therefore, for UK CR, a one size fits all approach is ineffective and a shift from predictive equations and submaximal exercise tests to gold-standard CPET on entry to CR would be required to improve exercise prescription. However, this may not be viable for a number of reasons, meaning that adoption of less conservative guidelines could provide a solution to ensuring that a larger proportion of patients achieve a training stimulus. Furthermore, although
VO$_{2peak}$ did not demonstrate a mode dependency, VAT did. This suggests that it may be
necessary to conduct a CPET using both modalities, or tailor exercise prescription based on
the modality used. Future research could confirm this mode dependency for HRR at VAT in
cardiac patients by testing the same group of patients twice, once during each modality.
Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflict of interest

The authors declare that there is no conflict of interest.

Author contributions

Both SP and SN have contributed equally to this manuscript, therefore we would like them both to be acknowledged as joint first authors. SN, SC and LI contributed to the design of the work. SN conducted data collection. SN, SB, SP and JP conducted data analysis and drafted the manuscript. SB, JP, SC, LI critically reviewed the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.
References:


Table 1. Clinical characteristics of patients grouped by exercise modality
Mean (95% CI) † = median and ranges

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pooled (cycle and treadmill data)</th>
<th>Cycle</th>
<th>Treadmill</th>
<th>P-value</th>
<th>Partial eta-squared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>100/14 (87.70% male)</td>
<td>40/4 (90.0% male)</td>
<td>60/10 (85.7% male)</td>
<td>0.411</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.25 (95% CI; 59.35 to 63.14)</td>
<td>63.13 (95% CI; 60.75 to 65.51)</td>
<td>58.25 (95% CI; 55.21 to 61.29)</td>
<td>0.012*</td>
<td>0.054</td>
</tr>
<tr>
<td>BMI (kg/m^2)</td>
<td>29.30 (95% CI; 28.54 to 30.07)</td>
<td>30.1 (95% CI; 28.8 to 31.44)</td>
<td>28.80 (95% CI; 29.74 to 27.90)</td>
<td>0.101</td>
<td>0.024</td>
</tr>
<tr>
<td>Resting SBP (mmHg)</td>
<td>131.55 (95% CI; 127.94 to 135.27)</td>
<td>139.57 (95% CI 134.39 to 144.95)</td>
<td>126.74(95% CI; 122.18 to 131.46)</td>
<td>0.001**</td>
<td>0.099</td>
</tr>
<tr>
<td>Resting DBP (mmHg)†</td>
<td>83 (60 to 149)</td>
<td>85.50 (62 to 104)</td>
<td>82 (60 to 149)</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>55.77 (95% CI; 54.34 to 57.20)</td>
<td>57.05 (95% CI; 54.35 to 59.75)</td>
<td>54.99 (95% CI; 53.35 to 56.62)</td>
<td>0.167</td>
<td>0.017</td>
</tr>
<tr>
<td>Resting HR (bpm)†</td>
<td>60 (42 to 95)</td>
<td>64 (44 to 95)</td>
<td>56 (42 to 91)</td>
<td>0.008**</td>
<td></td>
</tr>
</tbody>
</table>

BMI, Body mass index. kg·m⁻², kilogram per metre squared. SBP, systolic blood pressure. mmHg, millimetres of mercury. DBP, diastolic blood pressure. LVEF, left ventricular ejection fraction. HR, Heart Rate. Bpm, beats per minute.

*P<0.05, **P<0.01, ***P<0.001. †, Variables are reported as median (minimum and maximum) values and analysed using a non-parametric test.

Tr, transformed using log₁₀ transformation and reported as arithmetic mean for meaningful interpretation.
### Table 2. The occurrence of VAT in relation to predicted HRR training zones, stratified by exercise modality and baseline CRF levels

<table>
<thead>
<tr>
<th>Predicted HRR threshold</th>
<th>Number of patients (%)</th>
<th>Pooled cycle and treadmill</th>
<th>Cycle</th>
<th>Treadmill</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40% predicted HRR</td>
<td>51 (45.4%)</td>
<td>32 (76.2%)</td>
<td>19 (27.1%)</td>
<td></td>
</tr>
<tr>
<td>40-49% predicted HRR</td>
<td>24 (21.4%)</td>
<td>5 (11.9%)</td>
<td>19 (27.1%)</td>
<td></td>
</tr>
<tr>
<td>50-59% predicted HRR</td>
<td>15 (13.4%)</td>
<td>4 (9.5%)</td>
<td>11 (15.7%)</td>
<td></td>
</tr>
<tr>
<td>60-69% predicted HRR</td>
<td>11 (9.8%)</td>
<td>0</td>
<td>11 (15.7%)</td>
<td></td>
</tr>
<tr>
<td>&gt;70% predicted HRR</td>
<td>11 (9.8%)</td>
<td>1 (2.4%)</td>
<td>10 (14.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Total within 40-70% HRR</strong></td>
<td><strong>44.6%</strong></td>
<td><strong>21.4%</strong></td>
<td><strong>58.5%</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline CRF category</th>
<th>Low Fit</th>
<th>Mod Fit</th>
<th>High Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40% predicted HRR</td>
<td>24 (57.1%)</td>
<td>23 (46%)</td>
<td>4 (20%)</td>
</tr>
<tr>
<td>40-49% predicted HRR</td>
<td>11 (26.2%)</td>
<td>11 (22%)</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>50-59% predicted HRR</td>
<td>2 (4.8%)</td>
<td>8 (16%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>60-69% predicted HRR</td>
<td>2 (4.8%)</td>
<td>6 (12%)</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>&gt;70% predicted HRR</td>
<td>3 (7.1%)</td>
<td>2 (4%)</td>
<td>6 (30%)</td>
</tr>
<tr>
<td><strong>Total within 40-70% HRR</strong></td>
<td><strong>35.8%</strong></td>
<td><strong>50%</strong></td>
<td><strong>50%</strong></td>
</tr>
</tbody>
</table>

Predicted heart rate reserve using current guidelines, accounting for beta-blockade. Baseline fitness category based on Taylor et al. (2016); low fit ≤5 METs for women and ≤6 METs for men, mod fit = 5<7 METs for women and 6<8 METs for men, high fit ≥7 METs for women, and ≥8 METs for men. VAT, ventilatory anaerobic threshold. HRR, heart rate reserve. MET, metabolic equivalent where 1 MET = 3.5ml·kg⁻¹·min⁻¹.
Table 3. Cardiorespiratory data based on maximal CPET in patients using cycle and treadmill exercise modalities

<table>
<thead>
<tr>
<th></th>
<th>Pooled</th>
<th>Cycle</th>
<th>Treadmill</th>
<th>P-value</th>
<th>Partial eta-squared</th>
</tr>
</thead>
<tbody>
<tr>
<td>VO_{2peak} (L·min^{-1})</td>
<td>2.00 (95% CI; 1.88 to 2.11)</td>
<td>2.03 (95% CI; 1.82 to 2.25)</td>
<td>1.98 (95% CI; 1.83 to 2.12)</td>
<td>0.644</td>
<td>0.002</td>
</tr>
<tr>
<td>VO_{2peak} (ml·kg^{-1}·min^{-1}) Tr</td>
<td>22.12 (95% CI; 19.8 to 24.7)</td>
<td>21.43 (95% CI; 18.0 to 25.5)</td>
<td>22.55 (95% CI; 19.7 to 25.8)</td>
<td>0.359</td>
<td>0.008</td>
</tr>
<tr>
<td>HRmax (bpm)†</td>
<td>137 (88 to 181)</td>
<td>131 (88 to 181)</td>
<td>139 (88 to 169)</td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td>HRR (bpm)</td>
<td>71.5 (95% CI; 67.7 to 75.4)</td>
<td>65.1 (95% CI; 58.9 to 71.3)</td>
<td>75.43 (95% CI; 70.69 to 80.17)</td>
<td>0.009*</td>
<td>0.061</td>
</tr>
<tr>
<td>VAT (ml·kg^{-1}·min^{-1}) †</td>
<td>13.1 (8.2 to 29.7)</td>
<td>13.3 (8.2 to 26.0)</td>
<td>16.6 (8.6 to 30.0)</td>
<td>0.001***</td>
<td></td>
</tr>
<tr>
<td>VAT (L·min^{-1})†</td>
<td>1.3 (0.7 to 2.5)</td>
<td>1.15 (0.7 to 2.0)</td>
<td>1.35 (0.7 to 2.5)</td>
<td>0.027*</td>
<td></td>
</tr>
<tr>
<td>HR at VAT (bpm)</td>
<td>94 (95% CI; 91 to 97)</td>
<td>90 (95% CI; 85 to 94)</td>
<td>97 (95% CI; 93 to 101)</td>
<td>0.016*</td>
<td>0.05</td>
</tr>
<tr>
<td>VAT (% of VO_{2peak})</td>
<td>67.5 (95% CI; 65 to 70)</td>
<td>61.3 (95% CI; 58 to 65)</td>
<td>71.1 (95% CI; 68 to 74)</td>
<td>&lt;0.001***</td>
<td>0.151</td>
</tr>
<tr>
<td>VAT (% of predicted VO_{2peak}) Tr</td>
<td>56.8 (95% CI; 52 to 63)</td>
<td>51.8 (95% CI; 45 to 60)</td>
<td>60.1 (95% CI; 53 to 68)</td>
<td>0.003**</td>
<td>0.08</td>
</tr>
<tr>
<td>VAT (% of HRR)</td>
<td>45.90 (95%CI; 43 to 49)</td>
<td>39.45 (95%CI; 35.6 to 43.3)</td>
<td>49.77 (95%CI; 46.5 to 53.0)</td>
<td>&lt;0.001***</td>
<td>0.129</td>
</tr>
<tr>
<td>VAT (% of HRmax)</td>
<td>71.58 (95%CI; 70.1 to 73.1)</td>
<td>69.81 (95%CI; 66.9 to 72.7)</td>
<td>72.64 (95%CI; 70.9 to 74.4)</td>
<td>0.072</td>
<td>0.029</td>
</tr>
</tbody>
</table>

CPET, cardiopulmonary exercise test. VO2Peak, Peak oxygen consumption. HRmax, maximum heart rate. Bpm, beats per minute. HRR, heart rate reserve. VAT = ventilatory anaerobic threshold. HR, heart rate. *P<0.05, **P<0.01, ***P<0.001. †,Variables are reported as median (minimum and maximum) values analysed using a non-parametric test. Tr, transformed using log10 transformation and reported as arithmetic mean for meaningful interpretation.
Table 4. Relation between predicted and measured variables stratified by mode of exercise

<table>
<thead>
<tr>
<th></th>
<th>Pooled</th>
<th>Cycle</th>
<th>Treadmill</th>
<th>P-value</th>
<th>Partial etasquared</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Predicted HRmax</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(adjusted for β-blockade; bpm)†</td>
<td>136 (118 to 174)</td>
<td>138 (126 to 174)</td>
<td>134 (118 to 167)</td>
<td>0.009**</td>
<td></td>
</tr>
<tr>
<td><strong>VAT</strong> (% of predicted HRmax adjusted for β-blockade)</td>
<td>67.97 (65.86 to 70.07)</td>
<td>62.74 (59.68 to 65.80)</td>
<td>71.10 (68.50 to 73.71)</td>
<td>&lt;0.001*</td>
<td>0.131</td>
</tr>
<tr>
<td><strong>Predicted HRR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(adjusted for β-blockade; bpm)</td>
<td>77.85 (95% CI; 75.04 to 80.66)</td>
<td>77.93 (95% CI; 73.19 to 82.68)</td>
<td>77.8 (95% CI; 74.24 to 81.36)</td>
<td>0.965</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>VAT</strong> (% of predicted HRR adjusted for β-blockade)†</td>
<td>40.35 (9.57 to 87.93)</td>
<td>30.49 (9.57 to 69.23)</td>
<td>47.06 (12 to 87.93)</td>
<td>&lt;0.001*</td>
<td></td>
</tr>
<tr>
<td><strong>Predicted VO_{2\text{peak}}</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ml·min⁻¹)</td>
<td>2272.14 (95% CI; 2184.11 to 2360.17)</td>
<td>2258.79 (95% CI; 2114.05 to 2403.53)</td>
<td>2280.35 (95% CI; 2166.68 to 2394.01)</td>
<td>0.815</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>VO_{2\text{peak}}</strong> (% of Predicted VO_{2\text{peak}})</td>
<td>87.85 (95% CI; 84.11 to 91.58)</td>
<td>89.99 (95% CI; 82.64 to 97.35)</td>
<td>86.56 (95% CI; 82.40 to 90.72)</td>
<td>0.380</td>
<td>0.007</td>
</tr>
</tbody>
</table>

HRmax, maximal heart rate. Bpm, beats per minute. VAT, ventilatory anaerobic threshold. HRR, heart rate reserve. VO_{2\text{peak}}, peak oxygen consumption.

*P<0.05, **P<0.01, ***P<0.001. †, Variables are reported as median (minimum and maximum) values and analysed using a non-parametric test.
Predicted HRR using current guidelines, accounting for beta-blockade. Baseline CRF category based on Taylor et al. (2016); low fit <5 METs for women, and <6 METs for men, mod fit 5<7METs for women, and 6<8 METs for men, high fit ≥7 METs for women, and ≥8 METs for men. VAT, ventilatory anaerobic threshold. HRR, heart rate reserve. MET, metabolic equivalent where 1 MET = 3.5ml·kg⁻¹·min⁻¹.

<table>
<thead>
<tr>
<th></th>
<th>Low Fit</th>
<th></th>
<th>Mod Fit</th>
<th></th>
<th>High Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treadmill</td>
<td>25.9</td>
<td>48.6</td>
<td>40</td>
<td>61.3</td>
<td>51.7</td>
</tr>
<tr>
<td>Cycle</td>
<td>21.6</td>
<td>35.7</td>
<td>24.7</td>
<td>38.3</td>
<td>22.7</td>
</tr>
</tbody>
</table>

**Figure 1.** Inter-quartile range of VAT identification based on predicted HRR (% range) in cardiac patients separated by exercise modality and CRF category.
Figure 2a. A case study highlighting how the 40-70% HRR prediction equation may under-estimate individualised exercise prescription. A 58 year-old male taking beta-blockers with a BMI of 24.8, VO\textsubscript{2peak} of 35.28 ml·kg\(^{-1}\)·min\(^{-1}\) in the high fitness category. CPET was conducted on a treadmill. Solid line corresponds to heart rate at ventilatory anaerobic threshold, which is 125bpm.
Figure 2b. A case study highlighting how the 40-70% HRR prediction equation may over-estimate individualised exercise prescription. A 71 year-old male not taking beta-blockers with a BMI of 25.8, VO2peak of 13.82 ml·kg⁻¹·min⁻¹ in the low fitness category. CPET was conducted on a cycle. Solid line corresponds to heart rate at ventilatory anaerobic threshold, which is 72bpm.
JOURNAL CONTRIBUTOR’S PUBLISHING AGREEMENT

To be completed by the owner of copyright in the Contribution

Title of Article: Application of the Ventilatory Anaerobic Threshold for Optimising Exercise

Journal: European Journal of Preventive Cardiology

All Author(s): Pymer S, Nichols S, Prosser J, Birkett ST, Carroll S, Ingle L

Corresponding Author: Prof Lee Ingle

Corr. Author Address: L.Ingle@hull.ac.uk or 0044 1482 463141 University of Hull, UK

Please read the full terms and conditions on the following pages, then complete, sign and return all pages of this Agreement to the Journal’s Editorial Office.

The author who signs this Agreement certifies that he/she is authorised to sign on behalf of him/herself and in the case of a multi-authored Contribution, on behalf of all other authors of the Contribution. The authors understand that they each have the option of signing and returning a separate copy of this Agreement. This Agreement may be signed and executed by e-mail (a scanned hard copy of the Agreement with your signature on it or a digital original copy with your electronic signature are equally acceptable), by traditional hard copy or by fax.

COPYRIGHT ASSIGNMENT

In consideration for publication in the above Journal, you hereby assign to the owner(s) (the ‘Proprietor’) of the Journal identified above (the Journal title subject to verification by SAGE Publishing (‘SAGE’) copyright in your article (‘Article’) and the accompanying abstract (all materials collectively referenced as the ‘Contribution’) prepared by you for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed.

If you or your funder wish your Contribution to be freely available online to non-subscribers immediately upon publication (gold open access), you can opt for it to be included in SAGE Choice, subject to payment of a publication fee. For further information, please visit SAGE Choice.

In the event you provide Supplemental Material to the Proprietor, you hereby grant to the Proprietor the non-exclusive right and licence to produce, publish and make available and to further sub-license the material, in whole or in part, for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed.

By signing this Contributor Agreement you agree both to the above provisions and to the Terms of the Agreement attached below.

Contributor Signature: ___________________________ Date signed: 06-03-19

You represent that the Contribution is owned by you unless one of the following is checked:

- If any author is an employee of the United States Government and prepared the Contribution as part of their official duties, please check here: □
  
  US Government Agency Name: ________________________________

- If any author prepared the Contribution at the direction of their employer, please have a representative of your employer sign below, and please check here: □
  
  Employer Name: __________________________________________
  
  Authorized Signature: __________________________ Date signed: ____________

*U.S. Government work. If the Contribution was not prepared as part of the Contributor’s official duties, it is not a U.S. Government work. If the Contribution was jointly authored, all the co-authors must have been U.S. Government employees at the time they prepared the Contribution in order for it to be a U.S. Government work; if any co-author was not a U.S. Government employee, then the Contribution is not a U.S. Government work. If the Contribution was prepared under a U.S. Government contract or grant, it is not a U.S. Government work - in such case, copyright is usually owned by the contractor or grantee.

If you are required to submit an addendum by your employer or research funding body, please make your request via email to contracts@sagepub.co.uk indicating the name of the Journal and the title of your paper.

Terms of the Agreement page 1 of 3
TERMS OF THE AGREEMENT

Warranties.
You warrant to the Proprietor and SAGE that the Contribution is your original work, that you have the full power and authority to enter into this Agreement and to convey the rights granted herein to the Proprietor and to submit the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, either in printed or electronic form, that you have obtained and enclose all necessary permissions for the reproduction of any copyright works not owned by you (including artistic works, e.g. illustrations, photographs, charts, maps, other visual material, etc.) contained in the Contribution and any Supplemental Material you provide and that you have acknowledged the source(s), that the Contribution and any Supplemental Material you provide contain no violation of any existing copyright, other third party rights or any defamatory or untrue statements and do not infringe any rights of others, and you agree to indemnify, defend and hold harmless the Proprietor and SAGE against any claims in respect of any breach of the above warranties. You further agree to be bound by the Terms of the Agreement provided herein as part of this Agreement which outline the circumstances under which the Contribution may be reused.

SAGE for its benefit in accordance with the provisions of the Contracts (Rights of Third Parties) Act 1999 hereby asserts its right to the protection of the above warranties and indemnities.

Declaration of Conflicts of Interest.
You certify that:
1. All forms of financial support, including pharmaceutical company support, are acknowledged in the Contribution.
2. Any commercial or financial involvements that might present an appearance of a conflict of interest related to the Contribution are disclosed in the covering letter accompanying the Contribution and all such potential conflicts of interest will be discussed with the Editor as to whether disclosure of this information with the published Contribution is to be made in the Journal.
3. You have not signed an agreement with any sponsor of the research reported in the Contribution that prevents you from publishing both positive and negative results or that forbids you from publishing this research without the prior approval of the sponsor.
4. You have checked in the manuscript submission guidelines whether this Journal requires a Declaration of Conflicts of Interest and complied with the requirements specified where such a policy exists.

It is not expected that the details of financial arrangements should be disclosed. If the Journal does require a Declaration of Conflicts of Interest and no conflicts of interest are declared, the following will be printed with your Contribution: "None Declared".

Supplemental Material.
Supplemental Material includes all material related to the Contribution, but not considered part of the Contribution, provided to the Proprietor by you as the Contributor. Supplemental Material may include but is not limited to datasets, audio-visual interviews including podcasts (audio only) and vodcasts (audio and visual), appendices, and additional text, charts, figures, illustrations, photographs, computer graphics, and film footage. Your grant of a non-exclusive right and licence for these materials to the Proprietor in no way restricts re-publication of Supplemental Material by you or anyone authorised by you.

Publishing Ethics & Legal Adherence.
Contributions found to be infringing this Agreement may be subject to withdrawal from publication (see Termination below) and/or be subject to corrective action. The Proprietor (and/or SAGE if SAGE is different than the Proprietor) reserves the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the Contribution; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

Contributor's Responsibilities with Respect to Third Party Materials.
You are responsible for: (i) including full attribution for any materials not original to the Contribution; (ii) securing and submitting with the Contribution written permissions for any third party materials allowing publication in all media and all languages throughout the world for the full legal term of copyright; and (iii) making any payments due for such permissions. SAGE is a signatory of the STM Permissions Guidelines, which may be reviewed online.

Terms of the Agreement page 2 of 3
Termination.
The Proprietor and SAGE, together in their absolute discretion, may determine that the Contribution should not be published in the Journal. If in the rare circumstance the decision is made not to publish the Contribution after accepting it for publication, then all rights in the Contribution granted to the Proprietor shall revert to you and this Agreement shall be of no further force and effect, and neither you nor the Proprietor nor SAGE will have any obligation to the other with respect to the Contribution.

General Provisions.
This Agreement shall be deemed to be a contract made in England and shall be construed and applied in all respects in accordance with English law and all the parties submit and agree to the jurisdiction of the English courts.

This Agreement may be executed in counterparts each of which shall be deemed the original, all of which together shall constitute one and the same Agreement. A faxed copy or other electronic copy shall be deemed as an original. This transaction may be conducted by electronic means and the parties authorize that their electronic signatures act as their legal signatures of this Agreement. This Agreement will be considered signed by a party when their electronic signature is transmitted. Such signature shall be treated in all respects as having the same effect as an original handwritten signature. (You are not required to conduct this transaction by electronic means or use an electronic signature, but if you do so, then you hereby give your authorization pursuant to this paragraph.)

No amendment or modification of any provision of this Agreement shall be valid or binding unless made in writing and signed by all parties.

This Agreement constitutes the entire agreement between the parties with respect to its subject matter, and supersedes all prior and contemporaneous agreements, understandings and representations. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions, and this Agreement shall be construed in all respects as if any invalid or unenforceable provision were omitted.

If any difference shall arise between you and the Proprietor touching the meaning of this Agreement or the rights and liabilities of the parties thereto, the same shall be referred to the arbitration of two persons (one to be named by each party) or their mutually agreed umpire, in accordance with the provision of the England Arbitration Act 1996 or any amending or substituted statute for the time being in force.

Consent for Commercial Electronic Messages.
You hereby provide your express consent for the Proprietor, its affiliates and licensees (expressly including SAGE, where SAGE is not the Proprietor), and their respective designees to contact you in connection with any business communication or other correspondence. The parties agree that such consent may be withdrawn by you at a later time by providing written notice (including by email) to the Proprietor (and/or SAGE if different than the Proprietor). This clause shall survive expiration or earlier termination of this Agreement.

For more information on copyright and permissions and SAGE’s publishing policies (including Ethics & Responsibility), please visit the SAGE Journal Author Gateway:
https://uk.sagepub.com/en-gb/eur/page/journal-author-gateway

SAGE will provide the Corresponding Author of the Contribution with an electronic copy of the Contribution. For information about how you may re-use the Contribution, please consult SAGE Journals Permissions:
https://uk.sagepub.com/en-gb/eur/journals-permissions

All commercial re-use of the published Contribution should be referred to SAGE.

Terms of the Agreement page 3 of 3
Click here to access/download

**Author Responsibility Form**
ejpc_authorship_responsibility_form.docx